论文部分内容阅读
吡非尼酮(prfenidone)是由美国Inter Mune生物制药公司研发、罗氏制药生产的纤维化抑制剂,于2014年10月15日获FDA批准在美国上市[1],商品名为Esbriet。该药用于治疗特发性肺纤维化(IPF),已于2008年2月在欧盟各国允许上市。吡非尼酮的中文化学名称:5-甲基-1-苯基-2-(1H)-吡啶酮;英文化学名称:5-methyl-1-phenylpyridin-2(1H)-one;分子式:C12H11NO;分子量:185.22;CAS登记号:53179-13-8。
Pf fentinone is a fibrosis inhibitor developed by Inter Mune Biopharmaceutical Company of the United States and manufactured by Roche Pharmaceuticals. It was approved by the FDA on October 15, 2014 and was marketed in the United States [1] under the trade name Esbriet. The drug is used to treat idiopathic pulmonary fibrosis (IPF) and was licensed in all EU countries in February 2008. Chinese name for pirfenidone: 5-methyl-1-phenylpyridin-2 (1H) -one; Molecular formula: C12H11NO ; Molecular weight: 185.22; CAS Registry Number: 53179-13-8.